MannKind Corporation

NasdaqGM:MNKD Voorraadrapport

Marktkapitalisatie: US$1.8b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MannKind Beheer

Beheer criteriumcontroles 4/4

De CEO MannKind's is Michael Castagna, benoemd in May2017, heeft een ambtstermijn van 7.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.07M, bestaande uit 9.9% salaris en 90.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.83% van de aandelen van het bedrijf, ter waarde $ 14.43M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.3 jaar en 4.7 jaar.

Belangrijke informatie

Michael Castagna

Algemeen directeur

US$7.1m

Totale compensatie

Percentage CEO-salaris9.9%
Dienstverband CEO7.4yrs
Eigendom CEO0.8%
Management gemiddelde ambtstermijn7.3yrs
Gemiddelde ambtstermijn bestuur4.7yrs

Recente managementupdates

Recent updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

Feb 15

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Jan 03
MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

May 15
Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27
MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22
Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

MannKind to co-promote Thyquidity

Dec 17

Analyse CEO-vergoeding

Hoe is Michael Castagna's beloning veranderd ten opzichte van MannKind's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

US$12m

Mar 31 2024n/an/a

US$8m

Dec 31 2023US$7mUS$702k

-US$12m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$4mUS$623k

-US$87m

Sep 30 2022n/an/a

-US$98m

Jun 30 2022n/an/a

-US$88m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$4mUS$598k

-US$81m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$4mUS$495k

-US$57m

Sep 30 2020n/an/a

-US$45m

Jun 30 2020n/an/a

-US$44m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$2mUS$511k

-US$52m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$61m

Mar 31 2019n/an/a

-US$71m

Dec 31 2018US$2mUS$500k

-US$87m

Sep 30 2018n/an/a

-US$110m

Jun 30 2018n/an/a

-US$119m

Mar 31 2018n/an/a

-US$131m

Dec 31 2017US$1mUS$459k

-US$117m

Compensatie versus markt: De totale vergoeding ($USD 7.07M ) Michael } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Michael is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Michael Castagna (47 yo)

7.4yrs

Tenure

US$7,068,114

Compensatie

Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Michael Castagna
CEO & Director7.4yrsUS$7.07m0.83%
$ 14.9m
Lauren Sabella
Chief Operating Officer1.6yrsUS$2.74m0.026%
$ 455.6k
David Thomson
Executive VP22.8yrsUS$2.34m0.17%
$ 3.0m
Stuart Tross
Executive VP and Chief People & Workplace Officer7.8yrsUS$2.22m0.24%
$ 4.2m
Christopher Prentiss
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Sanjay Singh
Executive Vice President of Technical Operations2yrsUS$1.12m0.021%
$ 376.2k
Rosabel Alinaya
VP of Investor Relations & Treasury7.3yrsUS$519.59kgeen gegevens
John Bedard
Senior Vice President of Worldwide Regulatory Affairs19yrsgeen gegevensgeen gegevens
James McCauley
Chief Commercial Officer7.3yrsUS$921.51kgeen gegevens
Burkhard Blank
Executive VP of Research & Development and Chief Medical Officer1.4yrsgeen gegevens0.071%
$ 1.3m

7.3yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MNKD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Michael Castagna
CEO & Director7.4yrsUS$7.07m0.83%
$ 14.9m
Ronald Consiglio
Independent Director21yrsUS$241.73k0.043%
$ 767.5k
Kent Kresa
Chairman Emeritusless than a yearUS$240.64k0.096%
$ 1.7m
Christine Ann Mundkur
Independent Director5.9yrsUS$226.73k0.010%
$ 179.3k
Michael Friedman
Independent Director20.8yrsUS$229.23k0.0054%
$ 96.9k
Anthony Hooper
Independent Director4.8yrsUS$233.14k0.064%
$ 1.1m
James Shannon
Independent Chairman9.4yrsUS$255.64k0.0089%
$ 158.4k
Sabrina Kay
Independent Director3.8yrsUS$221.73k0.039%
$ 693.5k
Thomas Blevins
Member of Scientific Advisory Board3.2yrsgeen gegevensgeen gegevens
Jennifer Grancio
Independent Director4.6yrsUS$221.73k0.040%
$ 717.4k
Davida Kruger
Member of Scientific Advisory Board3.2yrsgeen gegevensgeen gegevens
Anders Carlson
Member of Scientific Advisory Board3.2yrsgeen gegevensgeen gegevens

4.7yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MNKD wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).